You are here:

aflibercept (Eylea)

Advice

following a full submission

aflibercept (Eylea®) is accepted for restricted use within NHS Scotland.

Indication under review: For adults for the treatment of visual impairment due to diabetic macular oedema (DMO).

SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.

Intravitreal aflibercept significantly improved BCVA at 52 weeks compared with laser photocoagulation in two phase III, double-masked studies.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHS Scotland.

Drug Details

Drug Name: aflibercept (Eylea)
SMC Drug ID: 1003/14
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: Treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.
BNF Category:
Sub Category: 11.8 Miscellaneous ophthalmic preparations
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 November 2014

Back